Vyome Holdings Reports Positive Phase 2 Results for VT-1953 in Malignant Fungating Wounds
核心洞察
Vyome Holdings (搜索) announced encouraging interim Phase 2 results for VT-1953 (搜索), demonstrating statistically significant reductions in malodor (P<0.001) in patients with malignant fungating wounds (搜索).
The topical agent also showed reductions in pain and improvements in quality of life while maintaining an excellent safety profile in the investigator-initiated study.
VT-1953 (搜索) targets a devastating condition affecting 5-14% of advanced cancer (搜索) patients, representing a potential $1 billion addressable market opportunity in the USA with no FDA-approved treatments currently available.
Vyome Holdings (搜索), Inc. (NASDAQ: HIND) announced encouraging interim Phase 2 results for its lead drug candidate VT-1953 (搜索), a topical agent designed to treat symptoms of malignant fungating wounds (搜索) (MFW) in cancer (搜索) patients. The investigator-initiated study demonstrated statistically significant reductions in malodor, the primary endpoint, with a p-value of less than 0.001.
Clinical Trial Results Show Promise
The interim Phase 2 data revealed that VT-1953 (搜索) successfully addressed the primary endpoint of malodor reduction in patients suffering from malignant fungating wounds (搜索). Beyond the primary endpoint, patients also reported reductions in pain and improvements in quality of life. The drug candidate maintained an excellent safety profile throughout the study period.
"The promising interim Phase 2 results for VT-1953 (搜索) reinforce the scientific promise of our immuno-inflammation platform," said Venkat Nelabhotla, CEO of Vyome. "With our disciplined operations, clean capital structure, and world-class team, we are well-positioned to deliver on the milestones ahead and drive long-term value for both shareholders and patients."
Addressing an Unmet Medical Need
Malignant fungating wounds (搜索) represent a devastating condition affecting 5-14% of advanced cancer (搜索) patients, with an estimated one million cancer patients afflicted by this inflammatory condition. The condition often leads to severe emotional and social burden due to extremely bad smell, which prevents interaction with family or friends.
Currently, there are no FDA-approved drugs for treating MFW, making VT-1953 (搜索) a potential first-in-class therapy. The addressable market opportunity represents approximately $1 billion in the USA, positioning VT-1953 as the only solution on the market if approved.
Development Timeline and Regulatory Strategy
Vyome is advancing VT-1953 (搜索) as a potential orphan drug candidate, with full Phase 2 data readouts expected to be announced in the first week of December 2025. The company has planned FDA discussions on pivotal study design and orphan drug designation for the first half of 2026.
Krishna Gupta, Chairman of Vyome, emphasized the significance of the opportunity: "We announced an important interim result for our drug targeting the billion-dollar opportunity in malignant fungating wound (MFW), and it's just the beginning!"
Pipeline Development
In addition to VT-1953 (搜索), Vyome reported strong preclinical efficacy for VT-1908 eye drops in uveitis (搜索) models during the third quarter, reinforcing its promise as a steroid-sparing candidate. FDA interactions for VT-1908 are also planned for the first half of 2026, alongside continued development activities to advance the program towards clinical readiness.
Financial Position and Corporate Updates
Following its successful Nasdaq listing, Vyome reported total cash, cash equivalents, and short-term investments of $5.7 million, providing an expected runway through the end of 2026. The company maintained disciplined operations, burning less cash than expected during its first quarter as a public company.
The company has strengthened its leadership team by adding a new CTO and SVP of Clinical Development, both bringing Big Pharma backgrounds and deep drug-development expertise across multiple FDA-approved therapies. Vyome also launched an AI strategy with the acquisition of MIT startup Oculo (搜索).